FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

11 letters match. Newest first.

  1. Nupack Inc.

    FDA warned Nupack Inc. that its dietary supplements were unapproved drugs and made without required manufacturing-practice records.

    High risk
  2. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  3. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  4. Vidaslim Co.

    Vidaslim Co. dietary supplements are adulterated by CGMP failures and misbranded by label violations.

    Medium
  5. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  6. ReNovo, Inc. DBA Provision Device Reprocessing Solutions

    ReNovo, a device reprocessor in Bend, Oregon, sold new device models without required FDA clearances and had quality system failures.

    High risk
  7. Intas Pharmaceuticals Limited

    FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.

    High risk
  8. Getsch+Hiller Medizintechnik GmbH

    FDA warned Getsch+Hiller about unapproved reusable laparoscopic tips and missing quality records at its German plant.

    High risk
  9. Aizu Olympus Co., Ltd.

    Aizu Olympus failed to validate endoscope designs and manufacturing processes and lacked MDR procedures, FDA says.

    High risk
  10. Monarch PCM, LLC

    Monarch PCM, LLC made unapproved skin drugs and broke manufacturing rules, with microbial contamination and weak investigations.

    High risk
  11. Miami University Department of Chemistry and Biochemistry

    Miami University contract testing lab falsified heparin API test data and lacked CGMP controls.

    High risk